Small Cell Lung Cancer in Light/Never Smokers - A Role for Molecular Testing?

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Small cell lung cancer (SCLC) is typically associated with heavy smoking.
• Driver mutations are increasingly identified in various cancer types, guiding treatment.
• Understanding SCLC heterogeneity and rare genetic alterations is crucial for effective management.

Purpose of the Study:

• To describe the management of SCLC transformation in an ALK-mutated patient.
• To report a de novo SCLC case with an ERBB2 alteration in a nonsmoker.
• To emphasize the role of molecular testing in specific SCLC patient populations.

Main Methods:

• Case report analysis of two distinct SCLC scenarios.
• Review of treatment strategies including chemotherapy and targeted inhibitors.
• Molecular testing for driver mutations (ALK, ERBB2) in SCLC patients.

Main Results:

• One patient with SCLC transformation and ALK mutation received chemotherapy followed by a targeted inhibitor.
• A separate de novo SCLC case in a nonsmoker revealed a potentially targetable ERBB2 alteration.
• Discordant response to chemotherapy suggested progression of the ALK inhibitor-sensitive component.

Conclusions:

• Molecular testing for driver mutations is recommended for SCLC patients with light or never smoking histories.
• Identifying targetable alterations like ALK and ERBB2 can inform optimal management strategies for SCLC.
• Further research is needed to understand the incidence and impact of driver mutations in specific SCLC subtypes.